08/20/2026
Ok, You guys are full of questions about peptides.
I LOVE peptide therapy.. initiated in an intelligent way.
Here is why I will not prescribe BPC 157 to a patient with a history of tumors or cancer.
BPC-157 has demonstrated pro-angiogenic activity in preclinical studies.
It activates the VEGFR2–Akt–eNOS pathway, promotes endothelial tube formation, and increases blood-vessel density. Primary study
Angiogenesis is beneficial for healing tendons, wounds and damaged tissue.
However, tumors can also use angiogenesis to obtain oxygen and nutrients, grow and potentially metastasize.
Some oncology treatments are specifically designed to block VEGF/VEGFR signaling. Giving an experimental peptide affecting the same pathway could theoretically work against that therapeutic objective.
BPC-157 has not been proven to cause cancer. However, because it can promote repair-related angiogenic signaling and has not undergone adequate human cancer-safety testing, we cannot exclude the possibility that it could support an existing tumor or increase recurrence risk. Therefore, the potential risk outweighs an unproven benefit in patients with active or recent cancer.
Sincerely,
Jessica Cornelison FNP BC
